Nanotech

Dosing underway for Phase 1 monotherapy study of NUV-868 in advanced solid tumors

Strong financial position provides cash runway through 2028; cash, cash equivalents and marketable securities of $703.8 million as of June 30, 2022

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today reported its financial results for the second quarter ended June 30, 2022, and provided a business update.

"We are committed to advancing innovative therapies as quickly and safely as possible for people with cancers that do not currently have adequate treatment options. As previously announced, this commitment has led us to re-prioritize our pipeline and focus on our BET inhibitor, NUV-868, which is progressing in an ongoing Phase 1 study, and our novel small molecule DDC platform," said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. "With $703.8 million in cash, cash equivalents and marketable securities as of June 30, 2022, and our experienced team — including our new Chief Medical Officer, David Liu, M.D., Ph.D., and our new Chief Regulatory Officer, Kerry Wentworth — we are well positioned to advance our programs for the benefit of patients and our stakeholders."

Recent Business Updates

NUV-868, BD2-Selective BETi : Advanced solid tumors

  • Dosing underway in the Phase 1 monotherapy study of NUV-868. The recently initiated Phase 1 study in advanced solid tumors, including ovarian, pancreatic, metastatic castration-resistant prostate and triple negative breast cancers, is designed to determine the safety and dose of NUV-868 to be used as a monotherapy and in combination with olaparib or enzalutamide for the Phase 2 and Phase 2b portions of the study.

Corporate Updates

  • Strengthened executive management team. The Company appointed David Liu, M.D., Ph.D., as Chief Medical Officer in July 2022, and Kerry Wentworth as Chief Regulatory Officer in May 2022. Both leaders are also part of the Executive Committee.

Second Quarter 2022 Financial Results

As of June 30, 2022, Nuvation Bio had cash, cash equivalents and marketable securities of $703.8 million.

For the three months ended June 30, 2022, research and development expenses were $28.9 million, compared to $14.0 million for the three months ended June 30, 2021. The increase was primarily due to a $12.3 million increase in third-party costs related to research services and manufacturing to advance our current preclinical programs and Phase 1/2 clinical trial, as well as a $2.5 million increase in personnel-related costs driven by an increase in headcount and stock-based compensation.

For the three months ended June 30, 2022, general and administrative expenses were $8.9 million, compared to $6.4 million for the three months ended June 30, 2021. The increase was primarily due to a $1.9 million increase in personnel-related costs driven by an increase in headcount and stock-based compensation, a $0.4 million increase in other miscellaneous expenses, a $0.1 million increase in legal fees, a $0.1 million increase in taxes, a $0.1 million increase in occupancy expenses, and a $0.1 million increase in insurance, offset by a $0.2 million decrease in professional fees.

For the three months ended June 30, 2022, Nuvation Bio reported a net loss of $34.9 million, or $0.16 per share. This compares to a net loss of $19.3 million, or $0.09 per share, for the comparable period in 2021.

On August 1, 2022, Nuvation Bio announced a restructuring, including a 35% workforce reduction, to reduce operating costs and align its organization with its re-prioritized development programs.

About Nuvation Bio

Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com .

Forward Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Nuvation Bio's cash runway and the potential therapeutic benefit of its product candidates. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with conducting drug discovery and initiating or conducting clinical trials due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; risks related to cost reduction efforts; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-Q to be filed with the SEC on or about August 4, 2022, under the heading "Risk Factors," and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

Nuvation Bio Inc. and Subsidiaries
Consolidated Balance Sheets
Unaudited
(In thousands, except share and per share data) June 30, December 31,

2022

2021

Assets
Current assets:
Cash and cash equivalents

$

102,321

$

132,423

Prepaid expenses and other current assets

7,799

3,642

Marketable securities

601,476

632,969

Interest receivable on marketable securities

2,668

3,039

Total current assets

714,264

772,073

Property and equipment, net

894

786

Operating lease right-of-use assets

4,442

2,871

Lease security deposit

138

421

Total assets

$

719,738

$

776,151

Liabilities and stockholders' equity
Current liabilities:
Accounts payable

$

12,728

$

3,925

Current operating lease liabilities

941

863

Accrued expenses

7,605

12,137

Total current liabilities

21,274

16,925

Warrant liability

1,633

11,037

Non-current operating lease liabilities

3,752

2,192

Total liabilities

26,659

30,154

Stockholders' equity
Class A and Class B common stock and additional paid in capital, $0.0001 par value per share; 1,060,000,000
(Class A 1,000,000,000, Class B 60,000,000) shares authorized as of June 30, 2022 and December 31, 2021,
218,244,300 (Class A 217,244,300, Class B 1,000,000) and 217,948,568 (Class A 216,948,568, Class B 1,000,000)
shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively

919,011

909,985

Accumulated deficit

(218,954

)

(162,803

)

Accumulated other comprehensive income

(6,978

)

(1,185

)

Total stockholders' equity

693,079

745,997

Total liabilities and stockholders' equity

$

719,738

$

776,151

Nuvation Bio Inc. and Subsidiaries
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share data)
Three Months Ended June 30, Six Months Ended June 30,

2022

2021

2022

2021

Operating expenses:
Research and development

$

28,922

$

14,034

$

49,650

$

29,913

General and administrative

8,948

6,400

16,411

11,005

Total operating expenses

37,870

20,434

66,061

40,918

Loss from operations

(37,870

)

(20,434

)

(66,061

)

(40,918

)

Other income (expense):
Interest income

841

776

1,798

1,214

Investment advisory fees

(215

)

(176

)

(384

)

(284

)

Change in fair value of warrant liability

3,080

500

9,404

207

Realized (loss) gain on marketable securities

(694

)

1

(908

)

46

Total other (expense) income, net

3,012

1,101

9,910

1,183

Loss before income taxes

(34,858

)

(19,333

)

(56,151

)

(39,735

)

Provision for income taxes

-

-

-

-

Net loss

$

(34,858

)

$

(19,333

)

$

(56,151

)

$

(39,735

)

Net loss attributable to common stockholders
Net loss per share attributable to common stockholders, basic and diluted

$

(0.16

)

$

(0.09

)

$

(0.26

)

$

(0.21

)

Weighted average common shares outstanding, basic and diluted

216,603

204,017

215,016

186,933

Comprehensive loss:
Net loss

$

(34,858

)

$

(19,333

)

$

(56,151

)

$

(39,735

)

Other comprehensive income, net of taxes:
Unrealized loss on available-for-sale securities

(761

)

(224

)

(5,793

)

(800

)

Comprehensive loss

$

(35,619

)

$

(19,557

)

$

(61,944

)

$

(40,535

)

Nuvation Bio Investors:
ir@nuvationbio.com

Nuvation Bio Media:
Argot Partners
Leo Vartorella
leo@argotpartners.com

News Provided by Business Wire via QuoteMedia

NUVB
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

Maraganore brings more than 35 years of scientific, research and development, capital markets and managerial leadership expertise to ProKidney

Fox joins Board with more than 25 years of healthcare investment banking, finance and capital markets experience

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program

Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program

Company prioritizes NUV-868, its BD2 selective BET inhibitor currently in a Phase 1 dose escalation study in advanced solid tumors, and its novel small molecule Drug-Drug Conjugate (DDC) platform

Company restructuring and cost savings associated with NUV-422 program discontinuation to extend cash runway through 2028

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer

Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer

Dr. Liu is a clinical leader who brings expertise in the discovery, development, and regulatory approval of oncology therapies worldwide

Ms. Wentworth has over two decades of industry experience in domestic and international regulatory and quality affairs

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors

Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the Food and Drug Administration (FDA) has placed a partial clinical hold on the Company's Phase 1 dose escalation study of NUV-422 in solid tumors, including high grade glioma, HR+/HER2- advanced breast cancer and metastatic castration resistant prostate cancer. The Company's Phase 1 trial began enrolling patients 19 months ago in December 2020 and, in recent months, was exploring higher doses to define a maximum tolerated dose. Following the emergence of uveitis, a form of inflammation in the eye, in certain patients receiving NUV-422, the Company proactively paused enrollment of new patients in order to further assess these adverse events with investigators and uveitis experts, and also reached out to the FDA for guidance around an appropriate path forward. While the partial hold is in place, no new patients will be enrolled in the NUV-422 program, although current study participants may continue to be treated in the Phase 1 study.

"We are committed to patient safety across all of our studies and to working collaboratively with the FDA to develop, as efficiently as possible, new medicines where existing therapies are inadequate," said David Hung, M.D., founder, president and chief executive officer of Nuvation Bio. "Based upon the recent development of uveitis as a potential safety signal, we will conduct an overall risk/benefit analysis of the NUV-422 program. Our goal is always to ensure that we deploy our resources on programs that have the highest probability of success and of generating value for patients and our investors. With $737.7 million in cash as of March 31, 2022, we are well positioned to continue developing all of our internal product candidates.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Universal Ibogaine Inc.

Universal Ibogaine Inc.

Universal Ibogaine Inc develops a platform of addiction treatment clinics, which use ibogaine as a primary modality for the interruption and ideally cessation of addictions to primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants. It runs addiction clinics it has a research partner clinic in Mexico.

SILO Pharma Inc

SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research.

Top 6 Nanotechnology Uses

Top 6 Nanotechnology Uses

While there’s been plenty of focus on apps and cloud computing in the technology space, advances are also being made in hardware-focused sectors such as nanotechnology.

Nanotechnology uses include everything from safer food processing to more efficient drug-delivery systems to tiny transistors that allow for smaller, more powerful computer chips. Unsurprisingly, nanotechnology applications are set to grow significantly in the coming years. The global nanotechnology market is projected to reach US$70.7 billion by 2026, growing at a compound annual growth rate of 9.2 percent between 2020 and 2026.

Still, for investors just starting to look at nanotechnology stocks, it can be difficult to know where to begin as nanotechnology applications are so varied. As a starting point, here’s an overview of six of the top areas in which nanoscience and nanotechnologies are making a big difference today.

Keep reading...Show less

NanoXplore Announces Management and Board Changes

NanoXplore Inc. (" NanoXplore " or the " Company ") (TSX: GRA and OTCQX: NNXPF) announces today that after more than eight years with NanoXplore, Luc Veilleux, CFO, will be departing the Company from his position on July 18, 2022 and will be joining VoltaXplore as CFO. He will remain with the Corporation until September 1, 2022 to ensure a smooth transition. Luc has over 25 years of executive management, financial and operational experience in manufacturing and mining industries. His previous roles include CFO of Mason Graphite, President of Maxi Canada, and CFO of Imerys Graphite and Carbon. Mr. Veilleux, with his work ethic and talent, made a major contribution to NanoXplore's development.

"On behalf of everyone at NanoXplore, I'd like to express my gratitude to Luc for his outstanding leadership, selfless partnership, and financial stewardship. Luc has played a crucial role in NanoXplore's success and growth by helping lay the solid foundation that supports the company's innovation, global presence and financial strength. I am looking forward to continue working with Luc in VoltaXplore" said Soroush Nazarpour, President and CEO, NanoXplore.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

NanoXplore Reports Improved Third-Quarter 2022 Financial Results

NanoXplore Inc. ("NanoXplore" or "the Company") (TSX: GRA and OTCQX: NNXPF), a world-leading graphene company, reported today financial results for the third quarter ended March 31, 2022.

HIGHLIGHTS

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

NanoXplore and Molding Products Execute Long Term Supply Agreement for GrapheneBlack Enhanced Composite Materials for Transportation Market

NanoXplore Inc. (" NanoXplore " or the " Corporation ") (TSX: GRA and OTCQX: NNXPF) announces that it has entered into a long-term supply agreement with Molding Products LLC to produce and sell graphene-enhanced Sheet Molding Compound ("SMC") called GrapheneBlack™ SMC, used to create high quality, lightweight composite exterior and battery enclosure parts for cars and trucks, such as hoods, bumpers, roofs, and battery packs. GrapheneBlack™ SMC delivers weight reduction of up to 15% vs typical composite parts while also improving surface finish, paintability, and crack resistance. Under the terms of the agreement, both companies can market and sell the new premium grade of SMC under the NanoXplore tradename. Weight reduction is becoming increasingly important for the transportation industry, particularly because electric vehicles are generally heavier than internal combustion engine vehicles and range anxiety could be addressed by reducing the weight of the vehicles. Furthermore, lightweight sheet molding composites are being used increasingly in electric vehicle battery packs that would be complementary to NanoXplore battery related activities.

The agreement with NanoXplore secures a competitive, localized supply of high-quality graphene to produce GrapheneBlack™ SMC as well as R&D support for the development of new graphene-enhanced product grades. NanoXplore is the world's largest manufacturer of sustainable, high-quality, cost-effective graphene with 4,000 metric tons of annual production capacity in Montreal, Canada.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×